Age-specific impact on the survival of gastric cancer patients with distant metastasis: an analysis of SEER database
16
Citation
38
Reference
10
Related Paper
Citation Trend
Abstract:
// Xinxing Li 1, * , Weijun Wang 1, * , Canping Ruan 1, * , Yi Wang 1, * , Haolu Wang 2 , Xiaowen Liang 2 , Yanping Sun 1 and Zhiqian Hu 1 1 Department of General Surgery, Changzheng Hospital, The Second Military Medical University, Shanghai, 200003, China 2 Therapeutics Research Centre, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia * These authors have contributed equally to this work Correspondence to: Xiaowen Liang, email: x.liang@uq.edu.au Yanping Sun, email: sunyanping2003@163.com Zhiqian Hu, email: huzhiq163@163.com Keywords: gastric cancer, distant metastasis, age, survival Received: December 08, 2016 Accepted: August 28, 2017 Published: September 28, 2017 ABSTRACT The age-specific impact on the survival of gastric cancer patients with distant metastasis is still unclear. In this study, we identified 11, 299 gastric cancer patients with distant metastasis between 2004 and 2013 from Surveillance, Epidemiology, and End Results population-based dataset. Patients were divided into young (≤60) and elderly groups (>60). Kaplan–Meier methods and multivariable Cox regression were used for the analysis of long-term survival outcomes and risk factors. There were significant differences between the two groups in terms of race, primary site, grade, histologic type, surgery, marital status and clinical T stage (P<0.05). The 1- and 3-year cancer specific survival rates were 29.0% and 6.2% in young group and 22.8% and 4.8% in elderly group in both univariate (X 2 =116.430, P<0.001) and multivariate analysis (P<0.001). Young patients had significantly better 1- and 3-year cancer specific survival than elderly patients in each T stage. Age was further validated as an independent survival factor in all T stages (T1, T2, T3, T4 and T X , P<0.05). In conclusion, age was an independent prognostic factor for gastric cancer patients with distant metastasis.Keywords:
Distant metastasis
Cite
Citations (0)
Objective:To explore the tduration related to distant metastases of nasopharyngeal carcinoma (NPC).Method:One hundred and three cases with confirmative diagnosis of NPC, in which the distant metastasis had happened before radiotherapy, were called the natural metastasis group. Another one hundred and thirty-eight cases, in which the distant metastasis had happened after radiotherapy, were called the metastasis after radiotherapy group. The clinical data and appearance time on distant metastasis from the two groups were analyzed.Result:It took 10.78 months (95%CI: 8.68~12.88) on average in the natural metastasis group from the primary symptom to the distant metastasis, and 20.77 months on average in the metastasis after radiotheraphy group. Comparing the two groups, there was highly remarkable difference (P0.01). The distant metastasis happened in 91.26% of the cases in the natural metastasis group in 2 years. And in 1 year and in 2 years, the distal metastasis incidences of the natural metastasis group was higher than those of the metastasis after radiotheraphy group by 34.41% and 28.94%, respectively. The distant metastasis happened in all cases in the natural metastasis group in 5 years, while in 2.9% of the cases in the metastasis after radiotherapy group beyond 5 years. There wasn't any obvious difference in the patients'sex and the appearce rate of the primary symptom (P0.05). But in the metastasis after radiotherapy group, the patients were younger and the T and N stages were earlier.Conclusion:The distal metastasis in the metastasis after radiotherapy group was at least 1~2 years later than that in the natural metastasis group. It was perhaps relative to the younger patients and the earlier stages.
Distant metastasis
Cite
Citations (0)
Distant metastasis
Surgical margin
Histology
Cite
Citations (120)
Objective To verify that combined detection of P53 protein and tumor markers in serum was better than any single marker detection on auxiliary diagnosis of the distant metastasis of digestive malignant neoplasm.Methods There were 55 post-operation patients with digestive malignant neoplasm diagnosed by pathology,all the cases were divided into metastasis group(19 cases with distant metastasis) and non-metastasis group(36 cases without distant metastasis),in addition to 14 healthy volunteers.We detected P53 protein and CEA,CA19-9,CA242,CA72-4 in serum by ELISA.Results The P53 level in serum in metastasis group were higher than that in non-metastasis group(P0.05),which in metastasis group and non-metastasis group were both higher than that in healthy control group(P0.05).P53,CA19-9,CA72-4 were risk factors of the distant metastasis of digestive malignant neoplasm.Applying the three to diagnose the distant metastasis of digestive malignant neoplasm,the sensitivities were respectively 84.2%,73.7%,47.4%,the specificities were respectively 100%,77.8%,97.2%.For parallel test of P53 and CA19-9,the sensitivity was 100.0%,the specificity was 61.1%.Conclusion P53 is a valuable single marker for auxiliary diagnosis of the distant metastasis of digestive malignant neoplasm.When P53 protein in serum is higher than 0.4086U/ml,it can be used to auxiliaryly positively diagnose the distant metastasis of digestive malignant neoplasm.When P53 and CA19-9 are both negative,it can be used to auxiliaryly deny the distant metastasis of digestive malignant neoplasm.
Neoplasm
Distant metastasis
Cite
Citations (0)
The latest results from the FLEX trial wag presented in ASCO annual meeting which was hold in June.2008 in Chicago.The study demonstrated that chemotherapy based on Cetuximab plus Cisplatin significantly increased the overall survival of NSCLC patients,including all histological subtypes.The new findings confirm that Erbitux is the first targeted thempy to show a significant survival benefit in NSCLC patients across all histological subtypes.
Key words:
Carcinoma,non-small-cell lung; Targeted therapy; Antibodies,monoelonal
Cite
Citations (0)
Cite
Citations (0)
Cite
Citations (6)
Objective To determine the efficacy and toxicity of docetaxel in patients with paclitaxel-resistant advanced non-small cell lung cancer (NSCLC). Methods The clinical data from 15 patients with NSCLC who were admitted in the Shanghai Chest Hospital from January 2005 to May 2008 were retrospectively analyzed. The effects and toxicities of the second-line treatment were assessed. The progression-free survival time(PFS) and overall survival time(OS) were analyzed. Results The disease control rate was 66.7 %, with a progression-free survival time of 6 months, and a overall survival time of 17.3 months. The 1-year survival rate was 63.3 %. The toxic effects were as expected. Conclusion The doeetaxel-based agent is active in patients with paelitaxel-resistant advanced NSCLC.
Key words:
Carcinoma, non-small-cell lung; Drug therapy doeetaxel
Progression-free survival
Cite
Citations (0)
Cite
Citations (0)
Correlations between treatment response and survival in patients with advanced non–small-cell lung cancer (NSCLC) have been unclear. Now, investigators have conducted a meta-analysis of 14 randomized, controlled trials of targeted and standard NSCLC therapies to examine associations between overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in 12,567 NSCLC patients.
At the trial level, ORR was strongly correlated with PFS (R2 =0.89), but no …
Progression-free survival
Complete response
Cite
Citations (0)